Document:

<PAGE>

                                                                   EXHIBIT 10.51

        THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933 OR ANY STATE SECURITIES LAWS AND MAY NOT BE
SOLD, EXCHANGED, HYPOTHECATED OR TRANSFERRED IN ANY MANNER EXCEPT PURSUANT TO A
REGISTRATION OR AN EXEMPTION FROM SUCH REGISTRATION.

                                PURCHASE WARRANT

                                   Issued to:

                        Fidelity National Financial, Inc.

                             Exercisable to Purchase

                         713,000 Shares of Common Stock

                                       of

                  FIDELITY NATIONAL INFORMATION SOLUTIONS, INC.

                          Void after September 24, 2006

<PAGE>

        This is to certify that, for the value described herein and subject to
the terms and conditions set forth below, the Warrantholder (hereinafter
defined) is entitled to purchase, and the Company (hereinafter defined) promises
and agrees to sell and issue to the Warrantholder, at any time on or after
September 24, 2001 and on or before September 24, 2006, up to 713,000 shares of
the Company's common stock at the Exercise Price (hereinafter defined).

        This Warrant Certificate is issued subject to the following terms and
conditions:

        1. Definitions of Certain Terms. Except as may be otherwise clearly
required by the context, the following terms have the following meanings:

        (a) "Cashless Exercise" means a partial exercise of the Warrants in
which, as payment of the Exercise Price thereof, the Warrantholder surrenders
for cancellation by the Company a portion of the Warrants not being exercised
that have a fair value (as hereinafter defined) equal to the aggregate Exercise
Price of the Shares being acquired on such Cashless Exercise. For purposes
hereof, the "fair value" of any Warrants surrendered for cancellation in a
Cashless Exercise shall be determined by (i) multiplying the number of the
Shares that would otherwise be purchasable if those surrendered Warrants were
then being exercised by the closing sale price for one share of Common Stock as
of the date of such exercise, as reported by the Nasdaq National Market and (ii)
subtracting from the product thereof the Exercise Price of those Shares. A
Holder may only elect a Cashless Exercise if the Securities issuable by the
Company on such exercise are publicly traded securities.

        (b) "Closing Date" means the date on which the Offering is closed.

        (c) "Commission" means the Securities and Exchange Commission.

        (d) "Common Stock" means the common stock, $0.001 par value, of the
Company.

        (e) "Company" means Fidelity National Information Solutions, Inc., a
Delaware corporation (Nasdaq: FNIS).

        (f) "Company's Expenses" means any and all expenses payable by the
Company or the Warrantholder in connection with an offering described in Section
6 hereof, except Warrantholder's Expenses.

        (g) "Exchange Act" means the Securities Exchange Act of 1934, as amended

        (h) "Exercise Price" means the price at which the Warrantholder may
purchase one Share upon exercise of Warrants as determined from time to time
pursuant to the provisions hereof. The initial Exercise Price is $10.00 per
Share.

                                       2
<PAGE>

        (i) "Participating Underwriter" means any underwriter participating in
the sale of the Securities pursuant to a registration under Section 6 of this
Warrant.

        (j) "Registrable Securities" means the Shares and any shares of capital
stock issued or issuable from time to time (with any adjustments) in exchange
for or otherwise with respect to the Shares.

        (k) "Registration Period" means the period beginning on the date hereof
and ending upon the latest to occur of:

     -    the third anniversary of the date upon which this Warrant expires;

     -    the date as of which no Warrantholder holds any Shares; and

     -    the date upon which all of the shares become salable without
          registration with the Commission pursuant to Rule 144(k) promulgated
          under the Securities Act.

        (l) "Registration Statement" means a Registration Statement of the
Company filed under the Securities Act.

        (m) "Rules and Regulations" means the rules and regulations of the
Commission adopted under the Securities Act.

        (n)    "Securities Act" means the Securities Act of 1933, as amended.

        (o) "Share" or "Shares" refers to one or more shares of Common Stock
issuable on exercise of the Warrant.

        (p) "Warrantholder" means a record holder of the Warrant or Securities.
The initial Warrantholder is Fidelity National Financial, Inc.

        (q) "Warrantholder's Expenses" means the sum of (i) the aggregate amount
of cash payments made to an underwriter, underwriting syndicate, or agent in
connection with an offering described in Section 6 hereof multiplied by a
fraction the numerator of which is the aggregate sales price of the Registrable
Securities sold by such underwriter, underwriting syndicate, or agent in such
offering and the denominator of which is the aggregate sales price of all of the
Company securities sold by such underwriter, underwriting syndicate, or agent in
such offering and (ii) all out-of-pocket expenses of the Warrantholder, except
for the fees and disbursements of one firm retained as legal counsel for the
Warrantholder that will be paid by the Company.

        (r) "Warrant" means the warrant evidenced by this certificate or any
certificate obtained upon transfer or partial exercise of the Warrant evidenced
by any such certificate.

                                       3
<PAGE>

        2. Exercise of Warrants. All or any part of the Warrant may be exercised
commencing on the Effective Date and ending at 5 p.m. Pacific Time on the fifth
anniversary of the Effective Date by surrendering the Warrant, together with
appropriate instructions, duly executed by the Warrantholder or by its duly
authorized attorney, at the office of the Company, 4050 Calle Real, Santa
Barbara, California 93110, Attention: President, or at such other office or
agency as the Company may designate. The date on which such instructions are
received by the Company shall be the date of exercise. If the Warrantholder has
elected a Cashless Exercise, such instructions shall so state. Upon receipt of
notice of exercise, the Company shall immediately instruct its transfer agent to
prepare certificates for the Securities to be received by the Warrantholder upon
completion of the Warrant exercise. When such certificates are prepared, the
Company shall notify the Warrantholder and deliver such certificates to the
Warrantholder or in accordance with the Warrantholder's instructions immediately
upon payment in full by the Warrantholder, in lawful money of the United States,
of the Exercise Price payable with respect to the Securities being purchased, if
any. If the Warrantholder shall provide the Company with an opinion of counsel
to the effect that such legend is not required, such certificates shall not bear
a legend with respect to the Securities Act.

        If fewer than all the Securities purchasable under the Warrant are
purchased, the Company will, upon such partial exercise, execute and deliver to
the Warrantholder a new Warrant Certificate (dated the date hereof), in form and
tenor similar to this Warrant Certificate, evidencing that portion of the
Warrant not exercised. The Securities to be obtained on exercise of the Warrant
will be deemed to have been issued, and any person exercising the Warrants will
be deemed to have become a holder of record of those Securities, as of the date
of the payment of the Exercise Price.

        3. Adjustments in Certain Events. The number, class, and price of the
Securities for which this Warrant is exercisable are subject to adjustment from
time to time upon the happening of certain events as follows:

        (a) If the outstanding shares of the Company's Common Stock are divided
into a greater number of shares or a dividend in stock is paid on the Common
Stock, the number of Shares for which the Warrant is then exercisable will be
proportionately increased and the Exercise Price will be proportionately
reduced; and, conversely, if the outstanding shares of Common Stock are combined
into a smaller number of shares of Common Stock, the number of Shares for which
the Warrant is then exercisable will be proportionately reduced and the Exercise
Price will be proportionately increased. The increases and reductions provided
for in this subsection 3(a) will be made with the intent and, as nearly as
practicable, the effect that neither the percentage of the total equity of the
Company obtainable on exercise of the Warrants nor the price payable for such
percentage upon such exercise will be affected by any event described in this
subsection 3(a).

        (b) In case of any change in the Common Stock through merger,
consolidation, reclassification, reorganization, partial or complete
liquidation, purchase of

                                       4
<PAGE>

substantially all the assets of the Company, or other change in the capital
structure of the Company, then, as a condition of such change, lawful and
adequate provision will be made so that the holder of this Warrant Certificate
will have the right thereafter to receive upon the exercise of the Warrant the
kind and amount of shares of stock or other securities or property to which he
would have been entitled if, immediately prior to such event, he had held the
number of Shares obtainable upon the exercise of the Warrant. In any such case,
appropriate adjustment will be made in the application of the provisions set
forth herein with respect to the rights and interest thereafter of the
Warrantholder, to the end that the provisions set forth herein will thereafter
be applicable, as nearly as reasonably may be, in relation to any shares of
stock or other property thereafter deliverable upon the exercise of the Warrant.
The Company will not permit any change in its capital structure to occur unless
the issuer of the shares of stock or other securities to be received by the
holder of this Warrant Certificate, if not the Company, agrees to be bound by
and comply with the provisions of this Warrant Certificate.

        (c) When any adjustment is required to be made in the number of Shares
or other securities or property purchasable upon exercise of the Warrant, the
Company will promptly determine the new number of such Shares or other
securities or property purchasable upon exercise of the Warrant and (i) prepare
and retain on file a statement describing in reasonable detail the method used
in arriving at the new number of such Shares or other securities or property
purchasable upon exercise of the Warrant and (ii) cause a copy of such statement
to be mailed to the Warrantholder within thirty (30) days after the date of the
event giving rise to the adjustment.

        (d) No fractional shares of Common Stock or other securities will be
issued in connection with the exercise of the Warrant, but the Company will pay,
in lieu of fractional shares, a cash payment therefor on the basis of the mean
between the bid and asked prices of the Common Stock in the over-the-counter
market or the closing price on a national securities exchange on the day
immediately prior to exercise.

        (e) If securities of the Company or securities of any subsidiary of the
Company are distributed pro rata to holders of Common Stock, such number of such
securities will be distributed to the Warrantholder or his assignee upon
exercise of this Warrant as the Warrantholder or assignee would have been
entitled to if the portion of the Warrant evidenced by this Warrant Certificate
had been exercised prior to the record date for such distribution. The
provisions with respect to adjustment of the Common Stock provided in this
Section 3 will also apply to the securities to which the Warrantholder or his
assignee is entitled under this subsection 3(e).

        (f) Notwithstanding anything herein to the contrary, there will be no
adjustment made hereunder on account of the sale of the Shares or other
Securities purchasable upon exercise of the Warrant.

        4. Reservation of Securities. The Company agrees that the number of
shares of Common Stock or other Securities sufficient to provide for the
exercise of the Warrant

                                       5
<PAGE>

upon the basis set forth above will at all times during the term of the Warrant
be reserved for exercise.

        5. Validity of Securities. All Securities delivered upon the exercise of
the Warrant will be duly and validly issued in accordance with their terms, and,
in the case of capital stock, will, when issued and delivered in accordance with
their terms against payment therefor as provided in the Warrant, be fully paid
and nonassessable, and the Company will pay all documentary and transfer taxes,
if any, in respect of the original issuance thereof upon exercise of the
Warrant.

        6. Registration of Securities Issuable on Exercise of Warrant
Certificate.

        (a) If, at any time prior to the expiration of the Registration Period,
a Registration Statement is not effective with respect to all of the Registrable
Securities and the Company decides to register any of its securities for its own
account or for the account of others, then the Company will promptly give the
Warrantholders written notice thereof and will use its best efforts to include
in such registration all or any part of the Registrable Securities requested by
such Warrantholders to be included therein (excluding any Registrable Securities
previously included in a Registration Statement). This requirement does not
apply to Company registrations on Form S-4 or S-8 or their equivalents relating
to equity securities to be issued solely in connection with an acquisition of
any entity or business or equity securities issuable in connection with stock
option or other employee benefit plans. Each Warrantholder must give its request
for registration under this paragraph to the Company in writing within 15 days
after receipt from the Company of notice of such pending registration. If the
registration for which the Company gives notice is a public offering involving
an underwriting, the Company will so advise the Investors as part of the
above-described written notice. In that event, if the managing underwriter(s) of
the public offering impose a limitation on the number of shares of Common Stock
that may be included in the Registration Statement because, in such
underwriter(s)' judgment, such limitation would be necessary to effect an
orderly public distribution, then the Company will be obligated to include only
such limited portion, if any, of the Registrable Securities with respect to
which such Warrantholders have requested inclusion hereunder. Any exclusion of
Registrable Securities will be made pro rata among all holders of the Company's
securities seeking to include shares of Common Stock in proportion to the number
of shares of Common Stock sought to be included by those holders. However, the
Company will not exclude any Registrable Securities unless the Company has first
excluded all outstanding securities the holders of which are not entitled by
right to inclusion of securities in such Registration Statement or are not
entitled pro rata inclusion with the Registrable Securities.

        (b) The Company will pay all of the Company's Expenses and each
Warrantholder will pay its pro rata share of the Warrantholder's Expenses
relating to the registration, offer, and sale of the Registrable Securities.

        (c) Except as specifically provided herein, the manner and conduct of
the registration, including the contents of the registration, will be entirely
in the control and

                                       6
<PAGE>

at the discretion of the Company. The Company will file such post-effective
amendments and supplements as may be necessary to maintain the currency of the
registration statement during the period of its use. In addition, if the
Warrantholder participating in the registration is advised by counsel that the
registration statement, in their opinion, is deficient in any material respect,
the Company will use its best efforts to cause the registration statement to be
amended to eliminate the concerns raised.

        (d) The Company will furnish to the Warrantholder the number of copies
of a prospectus, including a preliminary prospectus, in conformity with the
requirements of the Securities Act, and such other documents as it may
reasonably request in order to facilitate the disposition of the registered
Registrable Securities owned by it.

        (e) At the request of the Warrantholders who hold a majority in interest
of the Registrable Securities being sold pursuant to a Registration Statement
hereunder, and on the date that Registrable Securities are delivered to a
Participating Underwriter for sale in connection with the Registration
Statement, the Company will furnish to the Warrantholders and the Participating
Underwriter (i) a letter, dated such date, from the Company's independent
certified public accountants, in form and substance as is customarily given by
independent certified public accountants to underwriters in an underwritten
public offering, addressed to the Participating Underwriter; and (ii) an
opinion, dated such date, from counsel representing the Company for purposes of
the Registration Statement, in form and substance as is customarily given in an
underwritten public offering, addressed to the Participating Underwriter and
Warrantholders.

        7. Indemnification in Connection with Registration. In the event that
any Registrable Securities are included in a Registration Statement hereunder:

        (a) To the extent permitted by law, the Company will indemnify and hold
harmless each Warrantholder that holds such Registrable Securities, any
Participating Underwriter, any directors or officers of such Warrantholder or
such Participating Underwriter and any person who controls such Warrantholder or
such Participating Underwriter within the meaning of the Securities Act or the
Exchange Act (each, a "Warrantholder Indemnified Person") against any losses,
claims, damages, expenses or liabilities (collectively, and together with
actions, proceedings or inquiries by any regulatory or self-regulatory
organization, whether commenced or threatened in respect thereof, "Claims") to
which any of them become subject under the Securities Act, the Exchange Act or
otherwise, insofar as such Claims arise out of or are based upon any of the
following statements, omissions or violations in a Registration Statement filed
pursuant hereto, any post-effective amendment thereof or any prospectus included
therein: (i) any untrue statement or alleged untrue statement of a material fact
contained in the Registration Statement or any post-effective amendment thereof
or the omission or alleged omission to state therein a material fact required to
be stated therein or necessary to make the statements therein not misleading,
(ii) any untrue statement or alleged untrue statement of a material fact
contained in the prospectus (as it may be amended or supplemented) or the
omission or alleged omission to state therein any material fact necessary to
make the statements made therein, in light of the circumstances under which

                                       7
<PAGE>

the statements therein were made, not misleading, or (iii) any violation or
alleged violation by the Company of the Securities Act, the Exchange Act or any
other law, including without limitation any state securities law or any rule or
regulation thereunder (the matters in the foregoing clauses (i) through (iii)
being, collectively, "Violations"). Subject to the restrictions set forth in
subsection (c) below with respect to the number of legal counsel, the Company
will reimburse each Warrantholder Indemnified Person, promptly as such expenses
are incurred and are due and payable, for any legal fees or other reasonable
expenses incurred by them in connection with investigating or defending any
Claim. Notwithstanding anything to the contrary contained herein, the
indemnification agreement contained in this Section 7 does not apply to a Claim
by an Warrantholder Indemnified Person arising out of or based upon a Violation
that occurs in reliance upon and in conformity with information furnished in
writing to the Company by such Warrantholder Indemnified Person expressly for
use in connection with the preparation of the Registration Statement or any such
amendment thereof or supplement thereto; and does not apply to amounts paid in
settlement of any Claim if such settlement is made without the prior written
consent of the Company, which consent will not be unreasonably withheld. This
indemnity obligation will remain in full force and effect regardless of any
investigation made by or on behalf of the Warrantholder Indemnified Persons and
will survive any transfer of the Registrable Securities by the Warrantholders
made in accordance with this Warrant.

        (b) In connection with any Registration Statement in which a
Warrantholder is participating, each such Warrantholder will indemnify and hold
harmless, to the same extent and in the same manner set forth in subsection (a)
above, the Company, each of its directors, each of its officers who signs the
Registration Statement, each person, if any, who controls the Company within the
meaning of the Securities Act or the Exchange Act, and any other stockholder
selling securities pursuant to the Registration Statement or any of its
directors or officers or any person who controls such stockholder within the
meaning of the Securities Act or the Exchange Act (each a "Company Indemnified
Person") against any Claim to which any of them may become subject under the
Securities Act, the Exchange Act or otherwise, insofar as such Claim arises out
of or is based upon any Violation, in each case to the extent (and only to the
extent) that such Violation occurs in reliance upon and in conformity with
written information furnished to the Company by such Warrantholder expressly for
use in connection with such Registration Statement. Subject to the restrictions
set forth in subsection (c) below, such Warrantholder will promptly reimburse
each Company Indemnified Person for any legal or other expenses (promptly as
such expenses are incurred and due and payable) reasonably incurred by them in
connection with investigating or defending any such Claim. However, the
indemnity agreement contained in this Section 7 does not apply to amounts paid
in settlement of any Claim if such settlement is effected without the prior
written consent of such Warrantholder, which consent will not be unreasonably
withheld, and no Warrantholder will be liable under this Warrant (including this
Section 7 and Section 8 below) for the amount of any Claim that exceeds the net
proceeds actually received by such Warrantholder as a result of the sale of
Registrable Securities pursuant to such Registration Statement. This indemnity
will remain in full force and effect regardless of any investigation made by or
on behalf of a Company Indemnified Party

                                       8
<PAGE>

and will survive the transfer of the Registrable Securities by the Warrantholder
made in accordance with this Warrant.

        (c) Promptly after receipt by an Warrantholder Indemnified Person or
Company Indemnified Person (either, an "Indemnified Person") under this Section
7 of notice of the commencement of any action (including any governmental
action), such Indemnified Person will, if a Claim in respect thereof is to be
made against any indemnifying party under this Section 7, deliver to the
indemnifying party a written notice of the commencement thereof. The
indemnifying party may participate in, and, to the extent the indemnifying party
so desires, jointly with any other indemnifying party similarly given notice,
assume control of the defense thereof with counsel mutually satisfactory to the
indemnifying parties and the Indemnified Person. In that case, the indemnifying
party will diligently pursue such defense. If, in the reasonable opinion of
counsel retained by the indemnifying party, the representation by such counsel
of the Indemnified Person and the indemnifying party would be inappropriate due
to actual or potential conflicts of interest between the Indemnified Person and
any other party represented by such counsel in such proceeding or the actual or
potential defendants in, or targets of, any such action including the
Indemnified Person, and any such Indemnified Person reasonably determines that
there may be legal defenses available to such Indemnified Person that are
different from or in addition to those available to the indemnifying party, then
the Indemnified Person is entitled to assume such defense and may retain its own
counsel, with the fees and expenses to be paid by the indemnifying party. The
Company will pay for only one separate legal counsel for the Warrantholder
Indemnified Persons collectively, and such legal counsel will be selected by the
Warrantholders holding a majority in interest of the Registrable Securities. The
failure to deliver written notice to the indemnifying party within a reasonable
time of the commencement of any such action does not relieve an indemnifying
party of any liability to an Indemnified Person under this Section 7, except to
the extent that the indemnifying party is prejudiced in its ability to defend
such action. The indemnification required by this Section 7 will be made by
periodic payments of the amount thereof during the course of the investigation
or defense, as such expense, loss, damage or liability is incurred and is due
and payable.

        8. Contribution. To the extent that any indemnification provided for in
Section 7 above is prohibited or limited by law, the indemnifying party will
make the maximum contribution with respect to any amounts for which it would
otherwise be liable under Section 7 to the fullest extent permitted by law.
However, (a) no contribution will be made under circumstances where the maker
would not have been liable for indemnification under the fault standards set
forth in Section 7, (b) no seller of Registrable Securities guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act)
will be entitled to contribution from any seller of Registrable Securities who
was not guilty of such fraudulent misrepresentation, and (c) contribution
(together with any indemnification or other obligations under this Agreement) by
any seller of Registrable Securities will be limited in amount to the net amount
of proceeds received by such seller from the sale of such Registrable
Securities.

                                       9
<PAGE>

        9. Restrictions on Transfer. This Warrant may be sold, transferred,
assigned or hypothecated by Warrantholder, subject to applicable securities
laws. The Warrant may be divided or combined, upon request to the Company by the
Warrantholder, into a certificate or certificates evidencing the same aggregate
number of Warrants.

        10. No Rights as a Stockholder. Except as otherwise provided herein, the
Warrantholder will not, by virtue of ownership of the Warrant, be entitled to
any rights of a stockholder of the Company but will, upon written request to the
Company, be entitled to receive such quarterly or annual reports as the Company
distributes to its shareholders.

        11. Notice. Any notices required or permitted to be given under the
terms of this Warrant must be sent by certified or registered mail (return
receipt requested) or delivered personally or by courier (including a recognized
overnight delivery service) or by facsimile and will be effective five days
after being placed in the mail, if mailed by regular U.S. mail, or upon receipt,
if delivered personally, by courier (including a recognized overnight delivery
service) or by facsimile, in each case addressed to a party. The addresses for
such communications are:

        If to the Company:

        Fidelity National Information Solutions, Inc.
        4050 Calle Real
        Santa Barbara, California 93110-3413
        Attn:  President
        Fax:  (805) 696-7499

        If to a Warrantholder:

         Fidelity National Financial, Inc.
         4050 Calle Real
         Santa Barbara, California 93110
         Attention:  President
         Fax:  (805) 696-7812

Each party will provide written notice to the other parties of any change in its
address.

        12. Applicable Law. This Warrant will be governed by and construed in
accordance with the laws of the State of Delaware, without reference to conflict
of laws principles thereunder.

                           [signature page to follow]

                                       10
<PAGE>

        Dated as of September 24, 2001

FIDELITY NATIONAL INFORMATION SOLUTIONS, INC.

/s/ Eric Swenson
-----------------------------------------
By:  Eric Swenson
Its:  President and Chief Operating Officer

                                       11<PAGE>
                                                                    EXHIBIT 10.1

             Specific Co-Operation and Development Agreement No. 3*

*   Certain portions of this Exhibit have been omitted and filed separately
    under an application for confidential treatment.

<PAGE>

SCDA No. 3                                                    September 27, 2001

                            SPECIFIC CO-OPERATION AND

                              DEVELOPMENT AGREEMENT

                                      NO. 3

                     Software Product Development & License

                                   for [ *** ]

              Under General Co-operation and Development Agreement

                            Provided by OZ.COM Canada

1     GENERAL

1.1   THIS SPECIFIC DEVELOPMENT AND CONSULTING AGREEMENT No. 3 (this
      "Agreement") is made and entered into this 27th day of September 2001, by
      and between Microcell Labs Inc. ("MICROCELL"), a Canadian corporation with
      offices at 1250 Rene-Levesque Blvd West, Suite 400, Montreal, Quebec,
      Canada, and OZ.COM Canada Company ("OZ"), a Nova Scotia Company, with an
      office at 1100 de la Gauchetiere Street West, Suite 150, Montreal, Quebec,
      Canada, H3B 2S2 and is made under the general terms of a General
      Co-Operation and Development Agreement ("GCDA") entered into between OZ
      and MICROCELL on November 8, 2000.

1.2   The terms of the GCDA shall apply to this Agreement except where they are
      inconsistent with the terms of this Agreement, and the defined terms used
      in the GCDA shall have the same meaning in this Agreement, unless the
      context would obviously require otherwise.

2     NAMES OF COORDINATORS OF EACH PARTY

2.1   The coordinating party for OZ will be:

            Name:      Gilles Lapierre
            Address:   1100 de la Gauchetiere Street West
                       Montreal, Quebec, H3B 2S2, Canada

                                                                     Page 1 of 5

[***] These provisions have been omitted and filed separately under an
application for confidential treatment.

<PAGE>

SCDA No. 3                                                    September 27, 2001

            Tel:       +1 514-390-1333
            Email:     gilles.lapierre@oz.com

2.2   The coordinating party for MICROCELL will be:

            Name:      Jean-Marc Ferland
            Address:   1250 Rene Levesque Blvd. West, Suite 400
                       Montreal, Quebec,  H3B 4W8, Canada
            Tel:       +1 514-937-2121
            Email:     marc.ferland@microcell.ca

3     IDENTIFICATION OF PREEXISTING WORKS.

3.1   OZ shall have the discretion to determine the method, details, and means
      of performing the work. Notwithstanding any provision of this Agreement to
      the contrary, any routines, libraries, tools, methodologies, processes or
      technologies created, adapted or used by OZ in its business generally,
      including all associated intellectual property rights (collectively, the
      "Development Tools") shall be and remain the sole property of OZ, and
      MICROCELL shall have no interest in or ownership claim to such Development
      Tools. In addition, notwithstanding any provision of this Agreement to the
      contrary, OZ shall be free to use any ideas, concepts or know-how
      developed or acquired by OZ during that performance of this Agreement to
      the extent obtained and retained by OZ's personnel as impressions and
      general learning.

4     DESCRIPTION OF WORK PRODUCT

4.1   OZ agrees to provide, and MICROCELL agrees to acquire, the services and
      products described in Exhibit A and Exhibit B hereto ("Work Product").

4.2   All work shall be performed in a workmanlike and professional manner. OZ
      and MICROCELL shall develop appropriate administrative procedures for
      coordinating with each other. MICROCELL shall periodically provide OZ with
      evaluations of OZ's performance.

4.3   Work Product will include any written reports, concept descriptions,
      feature lists, marketing material, data compilations, feasibility studies,
      and any other media, materials, or other objects produced as a result of
      OZ's work or delivered by OZ in the course for performing that work. OZ
      agrees to maintain agreements or commitments from key personnel assigned
      to work on projects pertaining to this Agreement, so such personnel remain
      available for completion and follow-up support as reasonably appropriate
      in the interest of the resulting product.

                                                                     Page 2 of 5

<PAGE>

SCDA No. 3                                                    September 27, 2001

5     LICENSE TO USE THE WORK PRODUCT

5.1   License Grant. As per Section 8.2 of the GCDA, MICROCELL shall have the
      right to use the Work Product.

5.2   Term of Licence. As per Section 8.5 of the GCDA, license granted by this
      agreement to MICROCELL shall remain in effect for a period of three (3)
      years commencing on the date of acceptance of the Work Product.

6     FEES, EXPENSES, AND PAYMENT

6.1   In consideration of the Work Product to be delivered by OZ consistent with
      this Agreement, OZ shall be entitled to compensation as set forth in
      Exhibit A. In addition to these fees, MICROCELL shall pay OZ its actual
      out-of-pocket expenses as reasonably incurred by OZ in furtherance of its
      performance hereunder. OZ agrees to provide MICROCELL with access to such
      receipts, ledgers, and other records as may be reasonably appropriate for
      MICROCELL or its accountants to verify the amounts and nature of any such
      expenses.

6.2   On the statement date in the Performance Milestone and Price table as per
      Exhibit A, OZ shall deliver a statement to Microcell detailing charges
      based on work performed and expenses incurred during the period.
      Statements shall be delivered according to Exhibit A.

6.3   Parties agree that Revenue Sharing shall apply to Work Products made
      pursuant to this Agreement as provided by Section 7.3 of the GCDA . It is
      not clear at the time of entering into this Agreement whether the Work
      Products marketed by OZ will be sold or licensed independent of OZ's
      mPresence offering, or whether the Work Products will be sold or licensed
      to third parties at all. However, in the event that OZ (or its
      Affiliate(s)) sells or licenses the Work Products to third parties during
      the three-year period specified in the GCDA, OZ hereby confirms that it
      will pay to MICROCELL 10% of its net revenues (as defined in the GCDA)
      attributable to such sale(s) or license(s). The value attributable to the
      sale or license of the Work Products shall be the actual price charged to
      the customer for the particular product(s) or service(s) where such value
      is fixed. In the case Work Product is utilized to provide services or
      products to OZ's customers, the revenue base shall be calculated as the
      value for the specific service(s) or product(s) identified on the
      customer's invoice, less sales taxes (VAT, GST, PST and any similar tax)
      attributable to the service(s) or product(s). In the event that the Work
      Product is integrated into OZ's mPresence offering and cannot be
      differentiated, MICROCELL and OZ will negotiate in good faith the
      percentage of the value of the Work Product on the total value of the
      bundled product.

                                                                     Page 3 of 5

<PAGE>

SCDA No. 3                                                    September 27, 2001

7     DELIVERY AND ACCEPTANCE

7.1   OZ shall deliver each Work Product as per the Performance Milestones and
      Schedule table set forth in Exhibit A.

7.2   Acceptance of the Work Products will be made as follows:

            o     MICROCELL will be given full access to functional and
                  operational documentation pertaining to the Work Products for
                  review and inspection.

            o     MICROCELL will be given full access to test plan and test
                  report documents for review and inspection. The test
                  documentation will cover the entire testing cycle, including
                  functional, integration and system test activities.

            o     MICROCELL technical staff will be invited to participate to
                  the project testing activities to verify the product
                  performance in OZ lab environment.

7.3   MICROCELL shall issue a notice of acceptance or rejection pursuant to
      these acceptance and testing activities. Such notice shall be delivered
      and processed as per Section 4.2 of the GCDA.

8     LOCATION OF WORK FACILITIES

8.1   Substantially, all of the work will be conducted by OZ personnel at the OZ
      facility in Montreal using OZ tools and computing environment. If deemed
      appropriate for specific activities, OZ personnel could be working on a
      temporary basis at one of the MICROCELL locations in downtown Montreal.

9     OWNERSHIP AND INTELLECTUAL PROPERTY RIGHTS

9.1   Ownership of Work Product. In accordance with Section 8.1 of the GCDA, OZ
      shall be entitled to the full ownership of all rights, title and interest
      in Work Products and related Intellectual Property Rights.

9.2   Escrow. Upon request by Microcell, OZ shall deposit the software code of
      the Work Product, including software updates, with an escrow agent, agreed
      to by both parties, in accordance with Section 8.8 of the GCDA.

                                                                     Page 4 of 5

<PAGE>

SCDA No. 3                                                    September 27, 2001

10    TERM AND TERMINATION

10.1  Term. The term of this Agreement shall commence on the date set forth
      above and shall continue as per "Performance Milestones and Price" table
      included in Exhibit A.

10.2  Termination. Either party upon written notice may terminate this
      Agreement, if the other party performs a material breach of any obligation
      provided hereunder and the breaching party fails to cure such breach
      within sixty (60) days from the date of receipt of notice of such failure.

10.3  Survival. Notwithstanding any termination of this Agreement, the
      provisions of Sections 5.1, 5.2 and 6.3 shall remain in effect. In
      addition notwithstanding termination of the GCDA, Sections 1.2, 5.1, 5.2,
      6.3, 9.1 and 9.2 will also remain in effect.

      MICROCELL LABS INC.                        OZ.COM CANADA COMPANY

      By: /s/ Jean-Marc Ferland                  By: /s/ Gilles Lapierre
          -------------------------                  -------------------------

      Title: VP Labs                             Title:  VP OZ Canada

                                                                     Page 5 of 5

<PAGE>

Exhibit A to SCDA No. 3                                       September 27, 2001

                                    EXHIBIT A

                          TO SPECIFIC CO-OPERATION AND

                              DEVELOPMENT AGREEMENT

                                      NO. 3

                         Performance Milestones & Price

              Under General Co-operation and Development Agreement

                            Provided by OZ.COM Canada

1     1. GENERAL

      This SCDA is strictly related to the software development of a [ *** ]. A
      full product description is included in the attached Exhibit B to SCDA
      No.3.

1.1   Connections to other projects

      This project is related to the [ *** ], as it will result in the [ *** ]
      component supporting [ *** ] to/from users accessing the mPresence system
      with mobile phones.

      Development activities for the [ *** ] have been organized under project
      code name [ *** ] (platform) and [ *** ] (applications).

                                                                     Page 1 of 3

[***] These provisions have been omitted and filed separately under an
application for confidential treatment.

<PAGE>

Exhibit A to SCDA No. 3                                       September 27, 2001

2.    DEVELOPMENT SCHEDULE

      [***]

     Phase                                             Date of Completion
     -----                                             ------------------
     [***]                                              November 2, 2000
     [***]                                              November 27, 2000
     [***]                                              December 1, 2000
     [***]                                              December 29, 2000
     [***]                                              January 26, 2001
     [***]                                              February 14, 2001
     [***]                                              March 2, 2001
     [***]                                              March 23, 2001
     [***]                                              April 27, 2001

                                                                     Page 2 of 3

[***] These provisions have been omitted and filed separately under an
application for confidential treatment.

<PAGE>

Exhibit A to SCDA No. 3                                       September 27, 2001

3.    PERFORMANCE MILESTONES AND PRICE

      [***]

<TABLE>
<CAPTION>
Performance Milestone               Completed                    Price
--------------------------------------------------------------------------------
<S>                                 <C>                       <C>

[***]                                                         (1) CDN$ 31,402
                                                              (US$ 20,250)

[***]                                                         (2) CDN$ 252,173
                                                              (US$ 165,078)

[***]                                                         (3) CDN$ 37,121
                                                              (US$ 24,300)

[***]                                                         (4) CDN$ 137,017
                                                              (US$ 89,694)

SCDA No. 3 Grand Total              Upon date of              CDN$ 457,7121.4
                                    execution                 (US$ 299,332)
</TABLE>

-----------------------

(1)  1.00 Canadian dollar equals 0.6449 US dollar; Exchange rate, 15 Nov 2000:
     0.6449 (1.5507)

(2)  1.00 Canadian dollar equals 0.6546 US dollar; Exchange rate, 15 Feb 2001:
     0.6546 (1.5276)

(3)  1.00 Canadian dollar equals 0.6546 US dollar; Exchange rate, 15 Feb 2001:
     0.6546 (1.5276)

(4)  1.00 Canadian dollar equals 0.6546 US dollar; Exchange rate, 15 Feb 2001:
     0.6546 (1.5276)

                                                                     Page 3 of 3

[***] These provisions have been omitted and filed separately under an
application for confidential treatment.

<PAGE>

SCDA No. 3                                                    September 27, 2001

                                    EXHIBIT B

                          TO SPECIFIC CO-OPERATION AND

                              DEVELOPMENT AGREEMENT

                                      NO. 3

                                      [***]

                               PRODUCT DESCRIPTION

              Under General Co-operation and Development Agreement

                            Provided by OZ.COM Canada

                            [consisting of 10 pages]

                                      [***]

[***] These provisions have been omitted and filed separately under an
application for confidential treatment.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}]]